US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
US7214686B2
(en)
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
US6632823B1
(en)
*
|
1997-12-22 |
2003-10-14 |
Merck & Co., Inc. |
Substituted pyridine compounds useful as modulators of acetylcholine receptors
|
US6277870B1
(en)
*
|
1998-05-04 |
2001-08-21 |
Astra Ab |
Use
|
FR2804430B1
(fr)
*
|
2000-01-28 |
2002-03-22 |
Sanofi Synthelabo |
Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
|
GB0010955D0
(en)
|
2000-05-05 |
2000-06-28 |
Novartis Ag |
Organic compounds
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
WO2002016358A2
(en)
*
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
AU2001284645A1
(en)
*
|
2000-08-18 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
AU2001282873A1
(en)
*
|
2000-08-18 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
AU2001282875A1
(en)
|
2000-08-21 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
AU2001284646A1
(en)
|
2000-08-21 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
JP2004506734A
(ja)
*
|
2000-08-21 |
2004-03-04 |
ファルマシア・アンド・アップジョン・カンパニー |
疾患治療用のキヌクリド置換ヘテロアリール部分
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
WO2003018585A1
(en)
|
2001-08-24 |
2003-03-06 |
Pharmacia & Upjohn Company |
Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
|
WO2003018586A1
(en)
*
|
2001-08-24 |
2003-03-06 |
Pharmacia & Upjohn Company |
Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
|
EP1425286B1
(en)
*
|
2001-09-12 |
2007-02-28 |
Pharmacia & Upjohn Company LLC |
Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
|
PL369895A1
(en)
|
2001-10-02 |
2005-05-02 |
Pharmacia & Upjohn Company |
Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
|
US6849620B2
(en)
|
2001-10-26 |
2005-02-01 |
Pfizer Inc |
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
|
JP2005511613A
(ja)
|
2001-11-08 |
2005-04-28 |
ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー |
疾患治療用アザビシクロ置換ヘテロアリール化合物
|
CA2466344A1
(en)
|
2001-11-09 |
2003-05-22 |
Pharmacia & Upjohn Company |
Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
|
NZ533259A
(en)
|
2001-12-14 |
2007-10-26 |
Targacept Inc |
Methods and compositions for treatment of central nervous system disorders
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
EP1480977A2
(en)
|
2002-02-15 |
2004-12-01 |
PHARMACIA & UPJOHN COMPANY |
Substituted aryl compounds for treatment of disease
|
US6858613B2
(en)
*
|
2002-02-19 |
2005-02-22 |
Pfizer Inc. |
Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
|
JP2005523287A
(ja)
*
|
2002-02-19 |
2005-08-04 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
疾患治療用アザビシクロ化合物
|
JP2005525357A
(ja)
*
|
2002-02-20 |
2005-08-25 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
α7ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物
|
DE10211415A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Bicyclische N-Biarylamide
|
DE10211416A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Essig- und Propionsäureamide
|
EP1542999A1
(en)
|
2002-08-01 |
2005-06-22 |
Pharmacia & Upjohn Company LLC |
1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
|
JP2006501246A
(ja)
|
2002-08-30 |
2006-01-12 |
メモリー・ファーマシューティカルズ・コーポレイション |
神経変性疾患の治療において有用なアナバセイン誘導体
|
GB0220581D0
(en)
|
2002-09-04 |
2002-10-09 |
Novartis Ag |
Organic Compound
|
KR101129933B1
(ko)
|
2002-09-25 |
2012-03-23 |
메모리 파마슈티칼스 코포레이션 |
인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도
|
BR0315056A
(pt)
*
|
2002-11-01 |
2005-08-16 |
Pharmacia & Upjohn Co Llc |
Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
|
US7273872B2
(en)
*
|
2002-12-06 |
2007-09-25 |
The Feinstein Institute For Medical Research |
Inhibition of inflammation using α 7 receptor-binding cholinergic agonists
|
US7238715B2
(en)
*
|
2002-12-06 |
2007-07-03 |
The Feinstein Institute For Medical Research |
Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
|
CA2519265A1
(en)
*
|
2003-03-28 |
2004-10-07 |
Pharmacia & Upjohn Company Llc |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
GB0310867D0
(en)
|
2003-05-12 |
2003-06-18 |
Novartis Ag |
Organic compounds
|
DE10334724A1
(de)
*
|
2003-07-30 |
2005-02-24 |
Bayer Healthcare Ag |
N-Biarylamide
|
DK1678172T3
(da)
|
2003-10-15 |
2010-04-06 |
Targacept Inc |
Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet
|
PL1697378T3
(pl)
|
2003-12-22 |
2008-04-30 |
Memory Pharm Corp |
Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania
|
US20050137217A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
Spirocyclic quinuclidinic ether derivatives
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
JP4995075B2
(ja)
|
2004-03-25 |
2012-08-08 |
メモリー・ファーマシューティカルズ・コーポレイション |
インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用
|
US7488737B2
(en)
|
2004-04-22 |
2009-02-10 |
Memory Pharmaceutical Corporation |
Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
|
AU2005243147A1
(en)
|
2004-05-07 |
2005-11-24 |
Memory Pharmaceuticals Corporation |
1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
|
PE20060437A1
(es)
|
2004-06-18 |
2006-06-08 |
Novartis Ag |
COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
GB0424564D0
(en)
*
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
DE602005019094D1
(de)
|
2004-12-22 |
2010-03-11 |
Memory Pharmaceutical Corp |
Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
EP2298410B1
(en)
|
2004-12-27 |
2013-10-09 |
The Feinstein Institute for Medical Research |
Treating inflammatory disorders by electrical vagus nerve stimulation
|
EP1917265B1
(en)
|
2005-08-22 |
2010-09-29 |
Targacept, Inc. |
HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
|
US8106066B2
(en)
|
2005-09-23 |
2012-01-31 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
|
GB0521508D0
(en)
|
2005-10-21 |
2005-11-30 |
Novartis Ag |
Organic compounds
|
US8316104B2
(en)
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
TWI454262B
(zh)
*
|
2006-11-02 |
2014-10-01 |
Targacept Inc |
菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
|
CL2008000119A1
(es)
|
2007-01-16 |
2008-05-16 |
Wyeth Corp |
Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
|
KR20090107567A
(ko)
|
2007-02-09 |
2009-10-13 |
아스텔라스세이야쿠 가부시키가이샤 |
아자 가교환 화합물
|
TW200911808A
(en)
*
|
2007-07-23 |
2009-03-16 |
Astrazeneca Ab |
Novel compounds
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
US8391970B2
(en)
|
2007-08-27 |
2013-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
MX2010003375A
(es)
|
2007-10-01 |
2010-05-17 |
Comentis Inc |
Derivados de 1h-indol-3-carboxilato de quinuclidin-4-ilmetilo como ligandos del receptor de acetilcolina alfa 7 nicotinico para el tratamiento de enfermedad de alzheimer.
|
WO2009102962A2
(en)
|
2008-02-13 |
2009-08-20 |
Targacept, Inc. |
Combination of alpha 7 nicotinic agonists and antipsychotics
|
WO2009146030A1
(en)
|
2008-03-31 |
2009-12-03 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of t-cell activity
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
EA201001889A1
(ru)
|
2008-06-20 |
2011-08-30 |
Астразенека Аб |
Производные дибензотиазепина и их применение
|
EP2355893B1
(en)
|
2008-11-18 |
2013-12-25 |
Setpoint Medical Corporation |
Devices for optimizing electrode placement for anti-inflamatory stimulation
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
US20120094995A1
(en)
*
|
2009-01-28 |
2012-04-19 |
Astrazeneca Ab |
2-aza-bicyclo[2.2.1]heptane compounds and uses thereof
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
AU2010258792B2
(en)
|
2009-06-09 |
2015-07-02 |
Setpoint Medical Corporation |
Nerve cuff with pocket for leadless stimulator
|
FR2948368B1
(fr)
*
|
2009-07-21 |
2011-07-22 |
Servier Lab |
Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US11051744B2
(en)
|
2009-11-17 |
2021-07-06 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
AU2010336337B2
(en)
|
2009-12-23 |
2016-02-04 |
Setpoint Medical Corporation |
Neural stimulation devices and systems for treatment of chronic inflammation
|
AU2011256287B2
(en)
|
2010-05-17 |
2016-11-10 |
Envivo Pharmaceuticals, Inc. |
A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
|
WO2012024616A1
(en)
|
2010-08-19 |
2012-02-23 |
Buck Institute For Age Research |
Methods of treating miild cognitive impairment (mci) and related discorders
|
WO2012154865A2
(en)
|
2011-05-09 |
2012-11-15 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
GB201111705D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Compounds and their use
|
GB201111704D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Novel compounds
|
JO3115B1
(ar)
|
2011-08-22 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مركبات بيريدازينون واستخدامها كمثبطات daao
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
RU2017136693A
(ru)
|
2012-05-08 |
2019-02-08 |
Форум Фармасьютикалз, Инк. |
Способы поддержания, лечения или улучшения когнитивной функции
|
GB201209587D0
(en)
|
2012-05-30 |
2012-07-11 |
Takeda Pharmaceutical |
Therapeutic compounds
|
MA37975B2
(fr)
*
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
US9593106B2
(en)
|
2013-02-07 |
2017-03-14 |
Heptares Therapeutics Limited |
Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
|
CN108658970A
(zh)
|
2013-03-15 |
2018-10-16 |
建新公司 |
制备葡萄糖基神经酰胺合酶抑制剂的方法
|
CA2914263C
(en)
|
2013-06-21 |
2021-05-18 |
Takeda Pharmaceutical Company Limited |
1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
|
GB201314286D0
(en)
|
2013-08-08 |
2013-09-25 |
Takeda Pharmaceutical |
Therapeutic Compounds
|
GB201318222D0
(en)
|
2013-10-15 |
2013-11-27 |
Takeda Pharmaceutical |
Novel compounds
|
GB201320905D0
(en)
|
2013-11-27 |
2014-01-08 |
Takeda Pharmaceutical |
Therapeutic compounds
|
TW201613864A
(en)
|
2014-02-20 |
2016-04-16 |
Takeda Pharmaceutical |
Novel compounds
|
TW201617342A
(zh)
|
2014-07-11 |
2016-05-16 |
阿法馬根公司 |
調節α7活性之啶類
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
US11406833B2
(en)
|
2015-02-03 |
2022-08-09 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
WO2017127758A1
(en)
|
2016-01-20 |
2017-07-27 |
Setpoint Medical Corporation |
Implantable microstimulators and inductive charging systems
|
CN108882885A
(zh)
|
2016-01-20 |
2018-11-23 |
赛博恩特医疗器械公司 |
迷走神经刺激的控制
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
GB201616839D0
(en)
|
2016-10-04 |
2016-11-16 |
Takeda Pharmaceutical Company Limited |
Therapeutic compounds
|
GB201619514D0
(en)
|
2016-11-18 |
2017-01-04 |
Takeda Pharmaceuticals Co |
Novel compounds
|
DE102017210141A1
(de)
|
2017-06-16 |
2018-12-20 |
Henkel Ag & Co. Kgaa |
Portion zur Bereitstellung tensidhaltiger Flotten
|
US11173307B2
(en)
|
2017-08-14 |
2021-11-16 |
Setpoint Medical Corporation |
Vagus nerve stimulation pre-screening test
|
US11660443B2
(en)
|
2018-04-20 |
2023-05-30 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
CN114641477B
(zh)
*
|
2019-11-15 |
2024-03-12 |
柳韩洋行 |
对葡萄糖神经酰胺合酶具有抑制活性的化合物或其药学上可接受的盐和包含其的药物组合物
|
EP4041733A4
(en)
*
|
2019-11-15 |
2023-08-30 |
Yuhan Corporation |
NOVEL DERIVATIVES CONTAINING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFUUR, OR A PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
JP2021138648A
(ja)
|
2020-03-04 |
2021-09-16 |
武田薬品工業株式会社 |
経口固形製剤
|
US11938324B2
(en)
|
2020-05-21 |
2024-03-26 |
The Feinstein Institutes For Medical Research |
Systems and methods for vagus nerve stimulation
|
AU2021311131A1
(en)
|
2020-07-24 |
2023-03-23 |
Genzyme Corporation |
Pharmaceutical compositions comprising venglustat
|
EP4308561A1
(en)
*
|
2021-05-11 |
2024-01-24 |
Yuhan Corporation |
Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
|